Antares Pharma (ATRS) Misses Q1 EPS by 2c

Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $6.17 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance